The neurological disease treatment developer took its funding to over $213m, completing a series C round led by SoftBank Vision Fund 2.

Internet and telecommunications group SoftBank’s Vision Fund 2 led a $100m series C round yesterday for Neuron23, a US-based developer of therapuetics for neurological and immune conditions.

Kleiner Perkins, Westlake Village BioPartners, Cowen Healthcare Investments, Redmile Group, Acorn Bioventures, Cowen Healthcare Investments, HBM Partners, Perceptive Advisors and Surveyor Capital filled out the round.

Co-founded by biopharmaceutical company Origenis, Neuron23 uses genetic and artificial intelligence technology to develop treatments for a range of neurodegenerative, neuroinflammatory and systemic autoimmune diseases.

The series…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn